Xeris is developing its pipeline both through internal clinical development and external partnerships to advance the commercial potential of its products globally.
Xeris is interested in establishing a portfolio of strategic collaborations with key partners who wish to codevelop products using Xeris’ platform technologies (XeriSol™ and XeriJect™).
Currently, Xeris is working on a number of formulation feasibility programs in the areas of peptides, vaccines, and monoclonal antibodies.
We welcome the opportunity to discuss areas of potential common interest from which to build value for both parties.
To discuss partnering opportunities, please contact us.
We are proud to announce that as of October 5, 2021,
Xeris Pharmaceuticals, Inc. and Strongbridge Biopharma plc
are subsidiaries of Xeris Biopharma Holdings, Inc.
Not opening? Check to see you have pop-ups enabled or copy link below in a new window.https://ir.xerispharma.com/